HC Wainwright Issues Optimistic Forecast for VIGL Earnings

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Investment analysts at HC Wainwright upped their Q2 2025 earnings estimates for Vigil Neuroscience in a report released on Thursday, May 8th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.48) per share for the quarter, up from their prior forecast of ($0.58). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share. HC Wainwright also issued estimates for Vigil Neuroscience’s Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($1.93) EPS, FY2026 earnings at ($0.64) EPS, FY2027 earnings at $0.15 EPS and FY2028 earnings at $0.58 EPS.

Other equities research analysts have also issued research reports about the stock. William Blair raised shares of Vigil Neuroscience to a “strong-buy” rating in a research report on Thursday, April 24th. Guggenheim reissued a “buy” rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. Finally, Wedbush reissued an “outperform” rating and issued a $13.00 price objective on shares of Vigil Neuroscience in a research report on Monday, May 5th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $16.25.

Vigil Neuroscience Stock Performance

Shares of VIGL stock opened at $2.53 on Monday. Vigil Neuroscience has a one year low of $1.31 and a one year high of $6.06. The company has a 50 day moving average price of $1.94 and a 200 day moving average price of $2.29. The firm has a market capitalization of $118.08 million, a price-to-earnings ratio of -1.23 and a beta of 1.90.

Vigil Neuroscience (NASDAQ:VIGL) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04.

Hedge Funds Weigh In On Vigil Neuroscience

Several hedge funds have recently made changes to their positions in VIGL. Cubist Systematic Strategies LLC grew its stake in shares of Vigil Neuroscience by 53.0% in the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock worth $41,000 after purchasing an additional 8,358 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Vigil Neuroscience in the 4th quarter worth approximately $83,000. Barclays PLC increased its position in shares of Vigil Neuroscience by 43.6% in the fourth quarter. Barclays PLC now owns 64,049 shares of the company’s stock worth $109,000 after acquiring an additional 19,436 shares in the last quarter. Northern Trust Corp increased its position in shares of Vigil Neuroscience by 29.0% in the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock worth $110,000 after acquiring an additional 14,572 shares in the last quarter. Finally, Two Sigma Advisers LP increased its position in shares of Vigil Neuroscience by 243.8% in the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company’s stock worth $117,000 after acquiring an additional 49,000 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.